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Background: Clinical guidelines assist physicians to make decisions about suitable healthcare. We conducted a
controlled before-and-after study to investigate the impact of professional-led guideline workshops for patent
ductus arteriosus (PDA) management on physicians’ clinical practices, discharge mortality, and associated morbid
conditions among preterm neonates.
Methods: We recruited physicians practicing at two neonatal intensive care units (NICUs) in Japan and used the
data of all neonates weighing less than or equal to 1,500 g admitted to 90 NICUs (2 intervention NICUs and 88
control NICUs) in the Neonatal Research Network of Japan from April 2008 to March 2010. We held 1-day workshops
for physicians on PDA clinical practice guidelines at the two intervention NICUs. Physicians’ skills assessed by
confidence rating (CR) scores and the Sheffield Peer Review Assessment Tool (SPRAT) were compared between
pre- and post-workshop month at the intervention NICUs using Wilcoxon signed-rank tests. Neonatal discharge
mortality and morbidity were compared between pre- and post-workshop year at both the intervention and
control NICUs using multivariable regression analyses adjusting for potential confounders.
Results: Fifteen physicians were included in the study. Physicians’ CR scores (2.14 vs. 2.47, p = 0.02) and
SPRAT (4.14 vs. 4.50, p = 0.05) in PDA management improved after the workshops. The analyses of neonatal
outcomes included 294 and 6,234 neonates in the intervention and control NICUs, respectively. Neonates’ discharge
mortality declined sharply at the intervention NICUs (from 15/146 to 5/148, relative risk reduction −0.67; adjusted odds
ratio 0.30, 95% confidence interval 0.10 to 0.89) during the post-workshop period. The mortality reduction was much
greater than that in the control NICUs (from 207/3,322 to 147/2,912, relative risk reduction −0.19; adjusted odds ratio
0.75, 95% confidence interval 0.59 to 0.95), although the difference between the intervention and control NICUs were
not statistically significant.
Conclusions: Overall, physicians’ confidence in PDA management improved after attending guideline workshops.
Face-to-face workshops by guideline developers can be a useful strategy to improve physicians’ PDA management skills
and, thereby, might reduce PDA-associated mortality in preterm neonates.
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About 70% of preterm neonates at <28 weeks of gesta-
tional age are widely affected by patent ductus arteriosus
(PDA) [1], and about one-third of very low birth weight
(VLBW) neonates are symptomatic [2]. PDA is a cardiac
condition that might be associated with infant mortality
[3,4] and morbidity such as bronchopulmonary dysplasia
(BPD) [5,6], intraventricular hemorrhage (IVH) [7], and
necrotizing enterocolitis (NEC) [8,9]. No causality has
been established between PDA and these morbidities
[10,11] nor any evidence favoring specific treatment that
is likely to decrease the associated mortality or severe
morbidities; however, closure of PDA has been success-
ful [12]. Although numerous PDA therapies were uni-
versally accepted, in due course, they were proven
ineffective, harmful, and periodically catastrophic [13].
As a result, PDA management has been constrained by
complex uncertainties in diagnosis, allocation of clinical
priority, treatment identification, and preferred manage-
ment modality [14] that have led to gaps between evidence
and routine practice. Furthermore, different practices exist
within and between countries [15-17]. For instance, in
Japan, wide variations are reported in indomethacin use,
enteral feeding adjustment, fluid management, and ventila-
tion strategies, although diagnosis criteria between institu-
tions do not vary [18]. These inconsistencies have resulted
in confusion and uncertainty in the medical community
and raise questions about treatment ethics. Under these
uncertainties, standard PDA treatment should follow ‘risks
versus benefits’ rationale quantified by robust evidence
tailored to the conditions of individual neonates [10,11].
Translating research into daily practice and changing
physicians’ behavior could be a daunting challenge for
various reasons, e.g., the massive amount of generated
evidence [19] and different levels of healthcare system
delivery (e.g. professional and patient-level) might inhibit
practice change [19]. In such predicaments, clinical
guidelines might be useful to uphold treatment effective-
ness and to discourage ineffective treatment exercises
[20]. Among various educational strategies to endorse
professional practice and execution of research findings,
targeted planning e.g., outreach visits by experts, inter-
active workshops, and multifaceted program have shown
consistent usefulness, whereas the evidence was inconsist-
ent for the effectiveness of other strategies such as passive
dissemination of educational materials, involvement of
opinion leaders, audit and feedback, and instructive
educational sessions [19,21]. Also, the effectiveness of
the approaches may vary by types of target professional
performances, societal or cultural factors, and differences
in healthcare systems [21,22]. In neonatology, evidence on
effective educational methods is lacking except for that on
neonatal resuscitation [23,24]. An absence of effective
methods to implement guidelines therefore could eitherhinder the improvement of treatment quality or lead to
hazardous clinical outcomes, especially in a sensitive
population such as neonates.
Therefore, in this study, we hypothesized that work-
shops on PDA management guidelines by guideline
developers will have a positive effect on physicians’
change in practice and will thereby reduce the associ-
ated adverse outcomes in preterm neonates, including
mortality. We held face-to-face workshops at two
tertiary-level neonatal intensive care units (NICUs) in
Japan, which were used as intervention sites, and
sought to evaluate their impact on physicians’ routine
practices and clinical outcomes in premature neonates
with PDA before and after the workshops.
Methods
Study design, setting, and participants
This was a controlled before-and-after study conducted in
tertiary-level NICUs in Japan. The study included 15 phy-
sicians from two intervention NICUs—Kurashiki Central
Hospital (KCH) and Osaka Medical Center and Research
Institute for Maternal and Child Health (OMCRI-
MCH)—and all VLBW neonates weighing ≤1500 g admit-
ted to the Neonatal Research Network of Japan (NRNJ)
from April 2008 to March 2010. The two intervention
NICUs were selected by convenience and by the study
investigators. The included intervention sites were
eligible as they were the central NICUs providing
tertiary-level care in individual region. The NICUs offer
a range of crucial healthcare services such as obstetrics
and cardiac or general pediatric surgeries. At the point
of this study, the NICUs managed extremely preterm
neonates (22–25 weeks of gestational age), including
neonates with surgical requirement. The other NICUs
(N = 88) under the NRNJ network served as controls in
this study.
Intervention
We held 1-day workshops on the clinical practice guide-
line for PDA management in preterm neonates [25,26] in
February 2009 to assess the workshop impact on practice
change at KCH and OMCRI-MCH. The guideline used
in the workshop was developed according to the inter-
national standards for assessing the quality of practice
guidelines (AGREE) [27] and published originally in
Japanese [25,26]. All the recommendations made in the
Japanese guideline version were translated in English
and available as an Additional file 1. Two neonatologists
from the guideline development group organized and led
the workshops, which consisted of a 2-hour lecture on the
guidelines, a question-and-answer session, and case re-
views (Figure 1). The first half of the lecture focused on
the guideline development process, including question
selection, formulating recommendations from evidence
Figure 1 Flow diagram of the study. Legend: WS: workshop.
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Delphi process [28]. The remainder of the lecture pre-
sented the final recommendations of the guidelines and
their rationale. In the case reviews, the lecturers and partic-
ipants discussed several PDA cases (their clinical courses
and problems related to PDA). The case selection was
particularly driven by the usual difficulty surrounding
PDA management (e.g., poor response to the treatment
and delayed case detection) and related adverse out-
comes (respiratory deterioration, bowel problems, renal
failure, etc.).
It has been suggested that physicians’ practice change
could be hindered by various factors embedded deeply
in individual contexts; therefore, it is likely that the
change will vary from one setting to another [19]. Fur-
thermore, evidence effectiveness on multifaceted educa-
tional interventions, educational outreach visits, interactive
workshops, and several others are found consistent [21].
We therefore designed a multifaceted intervention consist-
ing of educational material (guidelines), educational out-
reach visits by content experts, face-to-face interactions
(question-and-answer sessions [Q&A] and case reviews),
and local consensus developing process (case reviews). The
national guideline and content experts helped overcome
the potential barriers possibly aroused from a lack of
motivation, leadership, knowledge, and skills to adopt
the current evidence and clinical practice change [19].The content experts were selected mainly based on
their proficient expertise in evidence-based medicine
and PDA management and experiences in organizing
similar educational training in Japan; however, they did
not receive any targeted training for this study. Case re-
views helped to develop a consensus for the implication
of the guidelines into the local context.
Participating physicians did not receive any information
about their outcome evaluation at baseline i.e., manage-
ment skill measures from confidence rating (CR) and
the Sheffield Peer Review Assessment Tool (SPRAT)
and neonates’ clinical outcomes. There were no interven-
tions in the control NICUs.
Outcome measures
Pre- and post-assessment of physicians’ PDA management
skills in the intervention NICUs
We assessed the impact of the workshops on physicians’
practice change 1 month before and after using a struc-
tured questionnaire on PDA management in the inter-
vention NICUs (KCH and OMCRI-MCH) only. We
evaluated confidence levels using CR scores [29] and
clinical skill assessment using SPRAT [30]. CR is a vali-
dated method to assess trainee physicians’ self-reported
confidence in a scale ranges from 1 to 4: not confident
(CR 1), satisfactory but lack confidence (CR 2), confident
in some cases (CR 3), and fully confident in most of the
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the CR for PDA diagnosis, prophylaxis, and treatment
management (Additional file 2). SPRAT was used to
peer review the participants and consists of 24 questions
covering good clinical care, good medical practice,
teaching and training, physician-patient relationships,
and working relationships with colleagues, plus an over-
all measurement [30]. Using a 6-grade performance
scale, in which 1 is the lowest and 6 is the highest, re-
viewers assigned the trainees as appropriate. The ques-
tions in SPRAT have been described previously [30].
One senior neonatologist from each of the intervention
sites (was not a workshop participant) rated the partici-
pants’ performance based on how well they complied
with the guideline recommendations for PDA manage-
ment (Additional file 1). The evaluation time of the
physicians’ practicing skill was selected arbitrary based
on our assumption that the change would require at
least a month to detect an intervention effect. We hypoth-
esized that without any educational training, physicians’
confidence and skill in daily practice would not change
in a month. Assessments for CR and SPRAT were not
approached in the control NICUs.
Neonatal data and endpoints in the intervention and
control NICUs
We reviewed data on VLBW neonates weighing ≤1500 g
admitted at the intervention NICUs from 1 April 2008
to 31 March 2010 and compared these data with the
VLBW neonates at the control NICUs of NRNJ. The
NRNJ is a large multicenter network, of which most
tertiary-level NICUs are members. We excluded neo-
nates with known congenital anomalies or moribund in-
fants (no resuscitative care administration was decided
at birth). Data abstractors collected data on VLBW neo-
nates admitted to all NICUs using a standard network
database operation manual. Primary outcomes were phy-
sicians’ PDA management skills and neonatal mortality
at discharge. Secondary outcomes included significant
PDA or PDA based on echocardiography; indomethacin
use to treat PDA; PDA ligation; respiratory distress syn-
drome (RDS); BPD defined as oxygen use at 36 weeks
corrected gestational age with oxygen use on 28th day
after birth; severe IVH of grade 3 or 4 [31]; periventricu-
lar leukomalacia (PVL); stage 2 NEC or higher based on
Bell’s criteria [32]; retinopathy of prematurity (ROP) of
grade 3 (middle, late) or above, as per Japanese ROP
grading guidelines; late onset sepsis; air leak syndrome;
and persistent pulmonary hypertension of the newborn
(PPHN).
Statistical analyses
The sample sizes (number of physicians and neonates)
were derived based upon practicality and feasibility ofavailable resources at the time this study was conducted.
As this was a pilot study, no existing relevant study from
Japan was available to justify our sample size calculation.
To assess the impact of the workshop, we compared
physicians’ skills (average CR and SPRAT scores in each
of their assessed domains) between pre- and post-
workshop period using Wilcoxon signed-rank test. The
maternal and neonatal characteristics were compared
between the pre- and post-workshop years (April 2008
to March 2009 and April 2009 to March 2010, respectively)
using Chi-square tests, Fisher’s exact tests, and t-tests.
Multivariable logistic regression analyses compared neo-
natal outcomes between pre- and post-workshop periods,
adjusting for potential confounders i.e., gender, gestational
age, Apgar score at 5 minutes, C-section, antenatal steroid
use, maternal hypertension, chorioamnionitis, outborn,
and the interaction term between the periods (pre- vs.
post-workshop) and sites (intervention vs. control NICUs).
A significant interaction term between the periods and
sites indicates a significant difference in the intervention
impact between the intervention and control NICUs. The
ORs with 95% confidence interval (CI) determination
in the regression model were separately reported for
both the intervention and control sites. We also con-
ducted difference-in-differences (DID) analysis for the
binary outcomes accounting for aggregate time effect
[33,34]. We addressed missing data using complete case
analyses and excluded observations with missing pre-
dictor variables. The data management and statistical
analyses were performed using PASW statistics 18.0
(SPSS Inc., Hong Kong) and SAS 9.3 (SAS Institute,
Inc., Cary, NC). A significant level of 2-sided p value <0.05
was used.
Ethical approval
This study was approved by the ethical committees of the
Kurashiki Central Hospital and Osaka Medical Center and
Research Institute for Maternal and Child Health. Written
informed consent for data collection and usage were
obtained from all physicians included in the study. Data
collection from the NRNJ database was approved by
the internal review board at the Tokyo Women’s Medical
University. Written informed consent for data collection
and usage at the NRNJ were obtained from the parents or
guardians of all included neonates.
Results
Physicians’ PDA management skills
Fifteen physicians participated in the workshops and
questionnaire (100% response rate; no missing data).
Following the workshops, this study found a significant
increase in overall CR (pre- vs. post-workshop: 2.14 vs.
2.47, p = 0.02) and a borderline increase in overall
SPRAT score (4.14 vs. 4.50, p = 0.05) (Table 1). Some
Table 1 Pre- and post-workshop comparisons of physicians’ PDA management skills
Confidence rating Pre-WS mean (SD) Post-WS mean (SD) p value
Prophylactic indomethacin 2.13 (0.99) 2.53 (1.13) 0.14
Treatment of symptomatic PDA 2.20 (0.86) 2.60 (0.99) 0.06
Decision of PDA ligation 1.87 (0.83) 2.40 (0.99) 0.02
Monitoring during indomethacin administration (e.g., signs and complications) 2.60 (0.91) 2.73 (0.80) 0.41
Other PDA treatments (e.g., transfusion, diuretics) 2.00 (0.76) 2.33 (0.82) 0.03
PDA treatments in chronic phase 1.87 (0.99) 2.20 (0.77) 0.21
Fluid management during PDA treatments 2.20 (0.94) 2.47 (0.83) 0.16
Respiratory management during PDA treatments 2.13 (0.74) 2.47 (0.83) 0.06
Nutrition during PDA treatments 2.27 (0.88) 2.47 (0.99) 0.32
Overall 2.14 (0.76) 2.47 (0.80) 0.02
Sheffield Peer Review Assessment Tool
Good clinical care 4.11 (0.56) 4.49 (0.76) 0.03
Maintain good medical practice 3.95 (0.52) 4.36 (0.77) 0.03
Teaching and training 4.10 (0.99) 4.43 (0.92) 0.04
Relationship with patients 4.67 (0.77) 4.89 (0.97) 0.08
Working relationships with colleagues 4.13 (0.36) 4.43 (0.73) 0.09
Overall 4.14 (0.42) 4.50 (0.71) 0.05
Wilcoxon signed-rank test was used, and p value <0.05 was considered statistically significant. There were no missing data. Pre-WS: before the workshops;
Post-WS: after the workshops; 95% CI: confidence interval; confidence rating score range: 1 to 4; Sheffield Peer Review Assessment Tool score range: 1 to 6
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teaching and training had marked post-workshop in-
creases (p = 0.03 and 0.04).
Maternal and neonatal characteristics
The analyses of neonates’ data included 294 (pre-work-
shop: 146; post-workshop: 148) and 6,234 (pre-workshop:
3,322; post-workshop: 2,912) neonates in the two inter-
vention NICUs and the other 88 control NICUs, respect-
ively. We observed a significant post-workshop difference
in chorioamnionitis and antenatal steroids use in both the
intervention and control NICUs as well as a significant in-
crease in maternal hypertension, premature rupture of the
membrane, and C-section in the control NICUs (Table 2).
Neonatal clinical outcomes
The odds of neonates’ discharge mortality improved sig-
nificantly (from 15/146 to 5/148, relative risk reduction
[RRR] −0.67; adjusted odds ratio [AOR] 0.30, 95% CI 0.1
to 0.89) during the post-workshop period, after adjusting
for potential covariates (Table 3). There was also a sig-
nificant mortality decline at the control sites (from 207/
3,322 to 147/2,912, RRR −0.19; AOR 0.75, 95% CI 0.59
to 0.95) during the same period, and it was greater in
the intervention sites than in the controls (Figure 2),
although no statistical significance was observed. (p =
0.075). Similarly, the difference in reduction of mortality
rate (−5.71%, 95% CI −11.6 to 0.12) between intervention
and control sites went in favor of the intervention sites,although no statistical significance was observed. Add-
itionally, we observed slight increases in the odds of a
few variables in the control sites only during the post-
workshop year. No significant differences for PDA,
indomethacin administration, and PDA ligation were
detected in the intervention and control sites.
Discussion
To our knowledge, this is the first study to examine the
effects of professional-led guidelines implementation
workshops on physicians’ management skills of PDA
and neonatal mortality and morbidities. We found that
face-to-face outreach visits by guideline developers were
effective in improving physicians’ confidence and skills
and may reduce mortality in preterm neonates.
Positive workshop impact in improving professionals’
practices and health outcomes is supported by an earlier
Cochrane review [22]. Our findings add further support
to the likelihood that changing physicians’ behavior is
achievable [35], even in a highly controversial field like
PDA [10-12,14,36]. Administered care could potentially
be unnecessary or harmful, if the new evidence uptake is
ineffectively practiced [37,38]. This is especially important
in Japan where preterm neonates are frequently monitored
by functional echocardiography before receiving tailored
care. Additionally, augmenting new evidence and a daily
recommended uptake [39] might be challenging for cli-
nicians [40]. Guideline translation could also be chal-
lenging due to its content and dissemination strategy
Table 2 Pre- and post-workshop comparisons of maternal and neonatal characteristics
Intervention NICUs (N = 2) Control NICUs (N = 88)
Variables Pre-WS (n = 146) Post-WS (n = 148) p value MD or OR (95% CI) Pre-WS (n = 3,322) Post-WS (n = 2,912) p value MD or OR (95% CI)
Maternal age (years) 31.2 ± 5.1 31.6 ± 5.4 0.56 0.43 (−0.78, 1.64) 31.2 ± 5.2 31.4 ± 5.3 0.37 0.12 (−0.15, 0.39)
Missing 1 0 166 47
Primipara 121 (82.9) 116 (78.4) 0.32 0.75 (0.42, 1.34) 2,836 (85.4) 2,514 (86.3) 0.27 1.08 (0.94, 1.25)
Multiple pregnancy 42 (28.8) 40 (27.0) 0.73 0.92 (0.55,1.53) 834 (25.1) 681 (23.4) 0.11 0.91 (0.81, 1.02)
Maternal hypertension 22 (15.1) 25 (16.9) 0.67 1.15 (0.61, 2.14) 625/3,320 (18.8) 589/2,815 (20.9) 0.04 1.14 (1.01, 1.29)
Maternal diabetes 3 (2.1) 3 (2.0) 0.98 0.99 (0.20, 4.97) 44/3,320 (1.3) 52/2,749 (1.9) 0.08 1.44 (0.96, 2.15)
PROM 51 (34.9) 47 (31.8) 0.56 0.87 (0.53, 1.41) 896/3,322 (26.9) 866/2,888 (30.0) <0.01 1.16 (1.04, 1.29)
Chorioamnionitis 19/146 (13.0) 46/146 (31.5) <0.01 3.08 (1.70, 5.58) 494/3,271 (15.1) 467/2,652 (17.6) <0.01 1.20 (1.05, 1.38)
Antenatal steroids use 80/146 (54.8) 97/147 (66.0) 0.05 1.6 (0.998, 2.57) 1,446/3,320 (43.6) 1,474/2,827 (52.1) <0.01 1.41 (1.28, 1.56)
Gestational age (weeks) 28.2 ± 3.6 28.4 ± 3.2 0.67 0.19 (−0.58, 0.98) 28.4 ± 3.2 28.3 ± 3.2 0.82 −0.02 (−0.14, 0.18)
Birth weight (grams) 1,001.2 ± 323.9 991.7 ± 322.3 0.8 −9.53 (−83.6, 64.5) 1,027.2 ± 303.6 1,032.7 ± 301.7 0.47 5.53 (−9.53, 20.59)
Birth length (cm) 34.8 ± 4.1 34.4 ± 4.5 0.45 −0.38 (−1.39, 0.62) 35.3 ± 4.0 35.3 ± 4.2 0.85 0.02 (−0.19, 0.23)
Missing 4 1 232 158
Head circumference (cm) 25.2 ± 2.7 25.4 ± 3.3 0.5 0.24 (−0.46, 0.95) 25.6 ± 2.8 25.6 ± 2.9 0.9 −0.01 (−0.16, 0.14)
Missing 8 1 296 188
Gender (male) 80 (54.8) 72 (48.7) 0.29 0.78 (0.49, 1.24) 1,670/3,322 (50.3) 1,505/2,911 (51.7) 0.26 1.06 (0.96, 1.17)
Outborn 9 (6.2) 5 (3.4) 0.26 0.53 (0.17, 1.63) 245 (7.4) 225 (7.7) 0.6 1.05 (0.87, 1.27)
Vertex presentation 95/146 (65.1) 100/144 (69.4) 0.42 1.22 (0.75, 1.99) 2,258/3,309 (68.2) 1,859/2,658 (70.0) 0.15 1.08 (0.97, 1.21)
Cesarean section 110 (75.3) 105 (70.9) 0.39 0.80 (0.48, 1.34) 2,502 (75.3) 2,268 (77.9) 0.02 1.15 (1.03, 1.30)
Apgar score < 7 at 5 min 36/145 (24.8) 36/148 (24.3) 0.92 0.97 (0.57, 1.66) 801/3,219 (24.9) 682/2,863 (23.8) 0.33 0.94 (0.84, 1.06)
Chi-square, Fisher’s exact test, or t-test was used as appropriate. p value <0.05 was considered statistically significant. All the estimates were rounded. Binary outcome variables with missing data are indicated by the
denominators showing the numbers of assessed infants. MD mean difference, OR odds ratio, CI confidence intervals. MD or OR estimates correspond as appropriate. Unless otherwise stated, values represent number of













Table 3 Pre- and post-workshop comparisons of neonatal clinical outcomes




n = 146 (%)
Post-WS
n = 148 (%)




DID in post- vs.
pre-WS (95% CI)**
Mortality 15 (10.3) 5 (3.4) 0.31 (0.11, 0.86)* 0.30 (0.1, 0.89)* 207 (6.2) 147 (5.1) 0.80 (0.64, 0.99)* 0.75 (0.59, 0.95)* −5.71 (−11.6, 0.12)
RDS 80 (54.8) 90 (60.8) 1.28 (0.81,2.04) 1.55 (0.90, 2.68) 1,893/3,322 (57.0) 1,682/,2884 (58.3) 1.06 (0.96, 1.17) 1.05 (0.93, 1.18) 4.68 (−6.86, 16.2)
BPD 25/141 (17.7) 36/147 (24.5) 1.51 (0.85, 2.67) 1.66 (0.90, 3.07) 490/3,282 (14.9) 504/2,858 (17.6) 1.22 (1.07,1.40)* 1.23 (1.06, 1.44)* 4.05 (−5.51, 13.6)
Severe IVH 6 (4.1) 8 (5.4) 1.33 (0.45, 3.94) 1.38 (0.45, 4.27) 145/3,322 (4.4) 126/2,882 (4.4) 1.00 (0.78, 1.28) 1.0 (0.77, 1.30) 1.29 (−3.68, 6.26)
PVL 3/146 (2.1) 6/143 (4.2) 2.09 (0.51, 8.51) 2.09 (0.51, 8.51) 112/3,318 (3.4) 91/2,864 (3.2) 0.94 (0.71, 1.24) 1.0 (0.75, 1.34) 2.34 (−1.77, 6.45)
ROP 14/139 (10.1) 17/140 (12.1) 1.23 (0.58, 2.61) 1.50 (0.66, 3.41) 289/2,429 (11.9) 360/2,512 (14.3) 1.23 (1.05, 1.46)* 1.33 (1.11, 1.60)* 0.36 (−7.97, 7.24)
NEC 3 (2.1) 3 (2.0) 0.98 (0.19, 4.97) 1.11 (0.22, 5.72) 55/3,322 (1.7) 53/2,889 (1.8) 1.11 (0.76, 1.62) 1.01 (0.68, 1.51) −0.21 (−3.5, 3.09)
Early sepsis 3 (2.1) 2 (1.4) 0.65 (0.11, 3.97) 0.65 (0.11, 3.97) 88 (2.6) 92 (3.2) 1.20 (0.89, 1.61) 1.27 (0.94,1.73) −1.21 (−4.29, 1.86)
Late sepsis 7 (4.8) 6 (4.1) 0.84 (0.27, 2.56) 0.93 (0.30, 2.91) 168/3,313 (5.1) 172/2,880 (6.0) 1.19 (0.95, 1.48) 1.17 (0.93, 1.48) −1.64 (−6.48, 3.20)
PDA 47 (32.2) 45 (30.4) 0.92 (0.56, 1.51) 0.97 (0.57, 1.65) 1,286/3,322 (38.7) 1,109/2,884 (38.5) 0.99 (0.89, 1.10) 0.95 (0.85, 1.07) −1.53 (−12.4, 9.35)
Indomethacin 43 (29.5) 44 (29.7) 1.01 (0.61, 1.67) 1.01 (0.64, 1.86) 1,229 (37.0) 1,054 (36.2) 0.97 (0.87, 1.07) 0.93 (0.83, 1.05) 1.08 (−9.63, 11.8)
PDA ligation 13 (8.9) 7 (4.7) 0.51 (0.20, 1.31) 0.46 (0.17, 1.23) 208/3,322 (6.3) 185/2,865 (6.5) 1.03 (0.84, 1.27) 0.96 (0.77, 1.20) −4.37 (−10.3, 1.51)
Air leak 7 (4.8) 4 (2.7) 0.55 (0.16, 1.93) 0.66 (0.17, 2.22) 88/3,322 (2.7) 93/2,880 (3.2) 1.23 (0.91, 1.65) 1.22 (0.90, 1.66) −2.67 (−7.09, 1.75)
PPHN 11 (7.5) 15 (10.1) 1.38 (0.61, 3.12) 1.33 (0.57, 3.17) 132/3,322 (4.0) 152/2,872 (5.3) 1.35 (1.06, 1.71)* 1.39 (1.09,1.79)* 1.28 (−5.28, 7.85)
Variables with missing data are indicated by the denominators showing the numbers of the assessed neonates. Covariates included in the multiple logistic regression models were gender, gestational age, Apgar score
< 7 at 5 minutes, cesarean section, antenatal steroids use, maternal hypertension, chorioamnionitis, and outborn.
Pre-WS: before the workshops; Post-WS: after the workshops. OR odds ratio, 95% CI 95% confidence interval, RDS respiratory distress syndrome, BPD bronchopulmonary dysplasia, IVH intraventricular hemorrhage, PVL
periventricular leukomalacia, ROP retinopathy of prematurity, NEC necrotizing enterocolitis, PDA patent ductus arteriosus, PPHN persistent pulmonary hypertension.
*Statistically significant at the 5% probability level; **DID: The difference in differences of neonatal outcomes (percentage points) = differences (%) between the post- and pre-WS for the intervention NICUs − differences













Figure 2 Mortality in intervention NICUs and control NICUs before
and after the workshop. Legend: VLBW: very low birth weight, WS:
workshop, NICUs: neonatal intensive care units.
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addressed in guideline implementation to influence physi-
cians’ routine practice [21]. Although no single strategy
has proven superior [19,41], our study provides support to
the effectiveness of a multifaceted educational intervention
consisting of educational material (clinical guideline),
expert outreach visits, and face-to-face interactive
meetings including local consensus developing process
(question-and-answer sessions and case reviews) to reduce
the gap between research and practice [21]. Additionally,
the effects of any targeted interventions for behavior
change are context-dependent [21]. A unique work envir-
onment surrounding Japanese physicians such as ex-
tremely long work hours [42] might make the workshop
more effective because it is often difficult for them to have
enough time to update their clinical knowledge and skill
without well-organized educational sessions.
Similar to the intervention sites, mortality reduction in
the control NICUs was also significant and was consist-
ent with previous findings that reported an ongoing,
marked improvement among VLBW neonates’ mortality
in Japan [43,44]. Although the reduction was greater in
the intervention sites compared to the controls, it was
not statistically significant; therefore, we could not dif-
ferentiate the positive workshop impact from the back-
ground declining trend of neonatal mortality. However,
this should not diminish the importance of our findings
because the guidelines were not intended to reduce PDA
and its treatment rate but to reduce the risks of associated
clinical deterioration and adverse outcomes by providing
tailored care for a specific neonatal condition. Though in-
significant, the PDA ligation rate in the intervention sites
dropped during the post-workshop period, which mayindicate an improvement in physicians’ PDA management
skills.
The strengths of our study include the use of a quasi-
experimental design, a national registry database, and
the employment of validated tools and standard guide-
line development methods [30]. This comprehensive
process might collectively influence physicians to comply
with recommendations and encourage better practice
adherence [19,45]. Our study has illustrated the potential
impact of the guidelines on neonatal clinical outcomes,
for which evidence is scarce [23,24]. Furthermore, our
quasi-experimental design provides important comple-
mentary information when relevant trials are limited
[46]. Our study has several limitations. First, our sample
size included a small number of workshop participants,
warranting larger sample sizes in future studies. Second,
physicians’ assessment of CR was self-reported, which
increases risk of recall bias. Although the SPRAT was
validated in a previous study including general pediatri-
cians at tertiary and secondary hospitals in the UK as a
multisource peer review tool [30], its reliability in this
study setting (neonatologists and pediatricians in Japanese
NICUs) as a single-source peer review was uncertain [30].
Third, due to a lack of information, we could not investi-
gate several management modalities, e.g., adoption of
prophylactic with indomethacin and fluid and nutrition.
Fourth, because of the study design, we could not exclude
the possibility that improved mortality rates were caused
by other factors. Fifth, although we conducted a 1-day
workshop due to the practicality and feasibility of the
available resources, more frequent workshops than a day-
long workshop in this study could have a large effect [47].
Finally, the external validity of this study is limited by the
setting (tertiary hospitals in Japan); therefore, the findings
must be interpreted with caution due to wide variations in
PDA management between institutions and countries.
Conclusions
Face-to-face workshops by guideline developers can be a
useful strategy to improve physicians’ confidence and skills
for PDA management and thereby might reduce PDA-
associated mortality in preterm neonates especially in
Japan. Our findings have added important knowledge to
this area at a time when evidence on effective guideline
implementation strategy in everyday practice is lacking,
particularly in Japan. We propose an enhanced uptake of
PDA management guidelines by increasing the number of
professional-led workshops in Japan to stimulate guideline
development and disseminate effective implementation
strategies for better practice adherence. Future studies
could provide further evidence by employing large multi-
center cluster randomized controlled trials to evaluate the
effectiveness of organization- and patient-oriented inter-
ventions [41].
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